January/February 2015

Utilization Impacts of New Oral Substitutes for Parenteral Cancer-Related Therapies

March 17, 2015

The American Journal of Pharmacy Benefits

Examination of changes in utilization, dose adequacy, and duration associated with market entry of the oral chelator deferasirox as a potential substitute for parenteral deferoxamine.

Drug-Induced Liver Injury in Children: Atomoxetine and Nonstimulants for ADHD

March 17, 2015

The American Journal of Pharmacy Benefits

Mechanisms of drug-induced liver injury in children, case reports of atomoxetine-induced liver injury in children, and nonstimulant options for attention-deficit/hyperactivity disorder.

Medication Management: Measuring What Matters

February 26, 2015

The American Journal of Pharmacy Benefits

As new care delivery models evolve to focus on value, accountability, and team-based care, new measure development opportunities exist to address care gaps and to support team-based care delivery systems and care transitions.

Defining the Teriparatide Patient: Osteoporosis Sequence of Care and Healthcare Resources

February 26, 2015

The American Journal of Pharmacy Benefits

This study provides real-world evidence of a teriparatide (TPTD) patient’s characteristics, sequence of care, and healthcare resource utilization, and compares TPTD patients with non-TPTD patients.

Costs of Collagenase Clostridium Histolyticum and Fasciectomy for Dupuytren's Contracture

February 25, 2015

The American Journal of Pharmacy Benefits

A retrospective cohort analysis was conducted to compare disease-specific healthcare resource utilization and the costs of collagenase clostridium histolyticum and fasciectomy among adult Dupuytren’s contracture patients.

In the Wake of Progress: Improving Clinical and Pharmacoeconomic Outcomes in the Management of Narcolepsy

February 25, 2015

The American Journal of Pharmacy Benefits

This CE activity will cover the clinical symptoms and pathophysiology of narcolepsy while addressing the economic and social burdens of this disease. A treatment monitoring plan and multidisciplinary strategies for selection of appropriate and cost-effective therapy will also be discussed.